the aid library

Filter

674

C20 Eight Proposed Recommendations for Effective G20 Agenda on Finance and Health

Civil Society 20 (C20) - Saudi Arabia 2020 (2020) CC

As a global community of +750 representatives of the world’s civil society, the C20 official Engagement Group of the G20 is submitting a list of policy priorities for the upcoming G20 Finance Ministers & Central Bank Governors meeting on July 18th and the G20 Extraordinary Sherpa Meeting on July 2 ... more

Nigeria: National Strategic Health Development Plan (NSHDP) 2010 - 2015

Federal Ministry of Health Nigeria (2010) C1

Integrating mental health into South Africa’s health system: current status and way forward

Schneider, M.; E. Baron, E. Breuer, et al. (2016) CC

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Gabon

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr ... more

Rapid assessment of Ebola impact on reproductive health services and service seeking behaviour in Sierra Leone

Government of Sierra Leone, Department for International Development, UN Population Fund, Irish Aid (2015)

The Johns Hopkins and Red Cross Red Crescent Public Health Guide in Emergencies
recommended

Johns Hopkins Bloomberg School of Public Health and International Federation of Red Cross and Red Crescent Societies (2008) C1

2nd edition. Essential guideline for humanitarian assistance

Water, Sanitation and Hygiene Situation in Health Care Facilities in Tanzania Mainland and Way Forward

National Institute for Medical Research (2016) C1

Implementation of Early Warning and Response with a focus on Event-Based Surveillance

World Health Organization WHO (2014) C_WHO

Early detection, assessment and response to acute public health events:

Public Health Emergency Management Guidelines for Ethiopia 2012

Ethiopian Health and Nutrition Research Institute Public Health Emergency Management Centre (2012) C1

Applying humanitarian standards to fight COVID-19

Sphere (2021) C_Sphere

Updated 8 June 2021. Coronavirus is spreading globally. How can individuals, communities, humanitarian actors, local and national authorities best respond to uphold the rights of all affected people?

Response to the Ukraine Crisis: interim report, February to June 2022

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

Saving lives is the priority of WHO’s response in Ukraine. WHO works to ensure time-critical, lifesaving multisectoral assistance, non-discriminatory access to emergency and essential health services and priority prevention programmes, and laying the foundation for longer-term health systems recov ... more

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Kenya

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr ... more

European Drug Report 2019: trends and developments.

European Monitoring Centre for Drugs and Drug Addiction European Union (2019) C1

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Ghana National Health Policy: Creating Wealth through Health

Ministry of Health Ghana; (2007) C1

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Comparative Study of Pharmaceutical Waste Disposal in Ethiopia, Kenya, Sudan and Uganda

Iosue, S. PSA Tansforming The Supply Chain (2020) C1

Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever -Revised and expanded edition

World Health Organization World Health Organization WHO Regional Office for South-East Asia WHO Regional Office for South-East Asia (2011) CC

Revised and expanded version of the Guidelines

Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement

World Health Organization WHO (2022) C_WHO

Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij ... more